Repare Therapeutics Inc. announced it has out-licensed its discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation. DCx is a newly-launched Canadian biotechnology company.
Under the terms of the agreement, Repare will receive a $1 million upfront payment and expects $3 million in near-term payments. The company will also hold a 9.99% equity position in DCx, which includes dilution protection rights.
Additionally, Repare is eligible for future out-licensing, clinical, and commercial milestone payments, along with low single-digit tiered sales royalties. This transaction allows Repare to focus on its clinical-stage pipeline while monetizing early-stage assets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.